Clinical Trial Technology Startup SignalPath Announces Successful Close of $18M Series B Funding Round
Summary
RALEIGH, N.C.--(BUSINESS WIRE)--SignalPath, a healthcare technology company reimagining the execution of clinical trials, announces the closing of their Series B funding round of $18M. This funding round supports the rapid growth of its network of leading community and academic health systems using the platform to manage their research portfolio as well as the continued expansion of SignalPath’s product suite. “As a founding member of the Board of Directors at SignalPath, I have been thrilled to see the rapid adoption of their innovative, intuitive research platform that drives ease and efficiency of trial execution at leading research sites around the country,” says Dr. Bob Harrington, Professor of Medicine, Stanford University. In light of the large network of sites and users on the platform, along with the breadth of the offering, SignalPath is now uniquely positioned to reimagine trials themselves. “Since the very beginning we believed that by providing intuitive software tools to research professionals that solved their key pain points and reduced complexity, we would drive efficiency, improve quality, and increase transparency across the research ecosystem,” says Dr. Brad Hirsch, Co-Founder & CEO at SignalPath.